Xenon Pharmaceuticals (XENE) is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for neurological disorders. XENE has an extensive knowledge of human genetics and diseases caused.
PLURISTEM (PSTI) a cell therapy company, developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions, company I’m following for years. Pluristem trading under.
Pluristem Therapeutics Inc. (PSTI) Nasdaq PLURISTEM (PSTI) a cell therapy company, developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions, company I’m.
Sarepta Therapeutics, Inc. (SRPT) Nasdaq A quick look at Sarepta’s yearly chart, from the spike to $63.73 after Exondys-51 FDA approval and the drop to $26.66 lowest point by Dec.
Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to.
Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in.
Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many.
Following my last technical analysis “XBI – A Look At The Near and Long Term In The Biotech Sector” I will start adding names to our watch list with.
SPDR S&P Biotech ETF (XBI)–NYSE We will maintain our focus on the XBI as the biotech barometer, many are waiting for the XBI to outperform the IBB again.
SPDR S&P Biotech ETF (XBI)–NYSE We will maintain our focus on the XBI as the biotech barometer. After the double bottom around 59 points a month ago, the.
Biotech traders have to adapt to any changes in the stock market, trying to adjust their trades and the game plan along with the markets condition. It is easier.
Sarepta Therapeutics, Inc. (SRPT) – Nasdaq After three years of a roller coaster, Sarepta getting closer to the the real deal, started with the NDA acceptance by the FDA on.
SPDR S&P Biotech ETF (XBI) We will maintain our focus on the XBI as the biotech barometer. Noticing lately the fact XBI is outperforming the IBB & the broader market.
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.
Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.
iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.
iShares Nasdaq Biotechnology (IBB) – Nasdaq Health Care Select Sector SPDR ETF (XLV)–NYSE The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV..
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.
SPDR S&P 500 ETF (SPY) –NYSE The SPY had an extreme price action during the last two months after reaching the All-Time-High 201.90 points on September 19th, followed by a.
Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach.
Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.
Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.
Merck & Co. Inc. (MRK) -NYSE Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal.
SPDR S&P 500 (SPY) –NYSE Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the.
Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid.
Bristol-Myers Squibb Company (BMY) –NYSE Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years.
Retrophin, Inc. (RTRX) –Nasdaq During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation.
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.
Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness.